Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil O Carragher

Showing results (41-50 of 112) with videos related to

Pageof 12
Sort By:
Bioorganic & Medicinal Chemistry|November 24, 2019
High content phenotypic screening identifies serotonin receptor modulators with selective activity upon breast cancer cell cycle and cytokine signaling pathwaysScott J Warchal, John C Dawson, Emelie Shepherd, et al.
Clinical and Translational Medicine|February 5, 2023
YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutationsRichard Cunningham, Siyang Jia, Krishna Purohit, et al.
RSC Medicinal Chemistry|November 4, 2024
Ligand-centred phenotype-driven development of potent kinase inhibitors against oesophageal cancerCecilia C Ayala-Aguilera, Yang Ge, Álvaro Lorente-Macías, et al.
Journal of Medicinal Chemistry|April 13, 2026
Discovery of a Highly Potent and Selective mTOR Inhibitor that Strongly Suppresses Glioblastoma Multiforme Cell GrowthÁlvaro Lorente-Macías, Jonathon Mok, John C Dawson, et al.
Pharmaceutics|December 7, 2013
Live cell in vitro and in vivo imaging applications: accelerating drug discoveryBeverley Isherwood, Paul Timpson, Ewan J McGhee, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 23, 2020
High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug DiscoveryRebecca E Hughes, Richard J R Elliott, Alison F Munro, et al.
Cancer Research|March 26, 2009
Real-time study of E-cadherin and membrane dynamics in living animals: implications for disease modeling and drug developmentAlan Serrels, Paul Timpson, Marta Canel, et al.
Journal of Biomolecular Screening|October 11, 2013
High-content analysis to leverage a robust phenotypic profiling approach to vascular modulationBeverley J Isherwood, Rebecca E Walls, Mark E Roberts, et al.
SLAS Discovery : Advancing Life Sciences R & D|June 3, 2021
Application of a High-Content Screening Assay Utilizing Primary Human Lung Fibroblasts to Identify Antifibrotic Drugs for Rapid Repurposing in COVID-19 PatientsJohn A Marwick, Richard J R Elliott, James Longden, et al.
Disease Models & Mechanisms|May 11, 2021
Automated in vivo drug screen in zebrafish identifies synapse-stabilising drugs with relevance to spinal muscular atrophyAna-Maria Oprişoreanu, Hannah L Smith, Sophia Krix, et al.
Pageof 12

Showing results (41-50 of 112) with videos related to

Sort By:
Pageof 12
Bioorganic & Medicinal Chemistry|November 24, 2019
High content phenotypic screening identifies serotonin receptor modulators with selective activity upon breast cancer cell cycle and cytokine signaling pathwaysScott J Warchal, John C Dawson, Emelie Shepherd, et al.
Clinical and Translational Medicine|February 5, 2023
YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutationsRichard Cunningham, Siyang Jia, Krishna Purohit, et al.
RSC Medicinal Chemistry|November 4, 2024
Ligand-centred phenotype-driven development of potent kinase inhibitors against oesophageal cancerCecilia C Ayala-Aguilera, Yang Ge, Álvaro Lorente-Macías, et al.
Journal of Medicinal Chemistry|April 13, 2026
Discovery of a Highly Potent and Selective mTOR Inhibitor that Strongly Suppresses Glioblastoma Multiforme Cell GrowthÁlvaro Lorente-Macías, Jonathon Mok, John C Dawson, et al.
Pharmaceutics|December 7, 2013
Live cell in vitro and in vivo imaging applications: accelerating drug discoveryBeverley Isherwood, Paul Timpson, Ewan J McGhee, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 23, 2020
High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug DiscoveryRebecca E Hughes, Richard J R Elliott, Alison F Munro, et al.
Cancer Research|March 26, 2009
Real-time study of E-cadherin and membrane dynamics in living animals: implications for disease modeling and drug developmentAlan Serrels, Paul Timpson, Marta Canel, et al.
Journal of Biomolecular Screening|October 11, 2013
High-content analysis to leverage a robust phenotypic profiling approach to vascular modulationBeverley J Isherwood, Rebecca E Walls, Mark E Roberts, et al.
SLAS Discovery : Advancing Life Sciences R & D|June 3, 2021
Application of a High-Content Screening Assay Utilizing Primary Human Lung Fibroblasts to Identify Antifibrotic Drugs for Rapid Repurposing in COVID-19 PatientsJohn A Marwick, Richard J R Elliott, James Longden, et al.
Disease Models & Mechanisms|May 11, 2021
Automated in vivo drug screen in zebrafish identifies synapse-stabilising drugs with relevance to spinal muscular atrophyAna-Maria Oprişoreanu, Hannah L Smith, Sophia Krix, et al.
Pageof 12